Jianfei Qian, PhD

Jianfei Qian received both his DVM and PhD in China. In 2002, he came to the US as a postdoctoral research fellow in Dr. Qing Yi’s lab at the University of Arkansas for Medical Sciences. In 2018, he was recruited as an assistant research professor at The Houston Methodist Research Institute. His research is focused on the development of novel immunotherapy methods to treat multiple myeloma (MM) and other cancers by using anti-tumor-specific monoclonal antibodies (mAbs), identifying new cancer-specific antigens, and developing novel tumor vaccines.

Qiang Wang, PhD

Qiang Wang received his PhD in Microbiology at University of Chinese Academy of Science where he focused on molecular mechanisms of Influenza A virus replication. During his postdoctoral training at Lerner Research Institute of Cleveland Clinic, Wang developed a series of experimental methods to investigate the cross-talk between the tumor microenvironment and multiple myeloma. He has broad interests in the regulation of myeloma intrinsic and extrinsic drug resistance. In his free time, he enjoys outdoor activities with his family, watching movies, and playing basketballs.

Liuling Xiao, PhD

Luiling graduated from Fudan University, Shanghai, China in 2017, and started the postdoctoral fellow training from September, 2017. My present project focuses on exploring the role of CD8+ T cells in the melanoma and multiple myeloma

Miao Xian, PhD

Miao Xian received her PhD in tumor pharmacology at Zhejiang University where she studied treatment of osteosarcoma and post translational modification of proteins. She joined Yi Lab in October 2019, working on tumor biology of multiple myeloma. Her research focuses on the role of bone marrow microenvironment in multiple myeloma. Miao enjoys go to concerts and music festivals in her free time.

Chuanchao Zhang, PhD

Chuanchao Zhang received his PhD degree in Beijing institute of Genomics, Chinese Academy of Science. He previously worked on DNA damage response, long non-coding RNAs and small peptides. He is well trained in molecular and cell biology and proficient in systematic analysis pipeline for high-throughput sequencing data, including RNA-seq, Chip-seq, PAR-CLIP-seq, etc. His current project focus is on the regulation of multiple myeloma and intrigued by tumor immunity, such as CAR-T. Looking forward to participating in related work in the future.

Yabo Li, PhD

Yabo Li received a joint PhD program at the College of Life Science in Lanzhou University (China) and the Lerner Research Institute in Cleveland Clinic (Ohio, USA). She joined the Yi lab in October 2022. She is interested in transcription factors regulating multiple myeloma (MM) cell proliferation and apoptosis. She’s using cell culture combined with in vivo mouse models to test some new compounds that target MM cells. Her current research is focused on regulation of myeloma drug resistance and targeted treatment in human MM. Yabo enjoys doing flower arrangement and painting when she is not hitting the lab bench or spending time with family and friends.